CorMedix (CRMD) Fundamental Analysis: Revenue, Earnings & Valuation

5.59 / 10

Netural

Fundamental rating is Neutral with a 5.6/10 score. Strengths include high inventory turnover, low cost‑of‑sales ratio and solid interest coverage, while current‑liabilities‑to‑total‑liabilities is high and asset‑to‑market‑value is weak. Overall fundamentals are fair but mixed.

Analysis Checks(8/10)

Revenue-MV

Value0.13

Score3/3

Weight56.71%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value617.03

Score2/3

Weight0.78%

1M Return0.13%

Inventory turnover ratio

Value1.93

Score3/3

Weight-5.57%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value41.41

Score0/3

Weight-23.96%

1M Return-4.96%

PB-ROE

Value-0.15

Score2/3

Weight52.89%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value1.28

Score2/3

Weight-2.01%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-6.57%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value617.03

Score2/3

Weight0.32%

1M Return0.05%

Cost of sales ratio (%)

Value11.54

Score3/3

Weight1.64%

1M Return0.26%

Asset-MV

Value-0.55

Score0/3

Weight25.77%

1M Return4.00%

Is CRMD undervalued or overvalued?

CRMD scores 5.59/10 on fundamentals and holds a Fair valuation at present. Backed by its 66.56% ROE, 52.31% net margin, 3.25 P/E ratio, 1.31 P/B ratio, and 850.00% earnings growth, these metrics solidify its Netural investment rating.